Assessment of iron deficiency anemia and role of iron therapy in sickle cell disease patients: A prospective study - NI

ICMR0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年1月22日

试验速览

暂无简介。

•1. Subjects in steady state, i.e. absence of clinical features of acute illness for at least 4 weeks prior to recruitment
•2. Confirmed for SCD-HbSS based on HPLC reports and molecular analysis
•3. Clinically having complaints of anemia (fatigue, weakness, lethargy, poor appetite, pica, reduced development and physical performance) and not having any symptoms but HbSS
•4. Those on Hydroxyurea (HU)

•1. Received iron supplements < 3 months prior to recruitment
•2. H/o BTx in < 3 months prior recruitment, H/o repeated transfusion = 5 units
•3. Severe anemia Hb < 7gm/dL
•4. Patients on iron chelation therapy, patients in acute crises
•5. Other diagnosed hemolytic diseases: thalassemia, G6PD deficiency, malaria, dengue
•6. Raised CRP ( > 5 mg/l), liver disease, clinically suspected hepatic disease
•7. Diagnosed malignancy
•8. Another micronutrient deficiency viz B12, folate/B9
•9. Denial of consent
•10. Non-compliant to Iron therapy

发起方

ICMR